Comprehensive molecular testing (PD-L1, EGFR, ALK) is no longer reserved for advanced disease. It is now critical for all patients with stage 1B or higher resectable NSCLC *before* starting any treatment to guide neoadjuvant and adjuvant therapy decisions.

Synthakyne's drug demonstrated a 75% response rate in lung cancer patients with STK11 and KEAP1 mutations, a subgroup where the published response rate for standard care is only 7%. This suggests the drug is highly effective in the most immunologically resistant patient populations, a significant differentiator.

The CheckMate 9LA regimen provides exceptional benefit to PD-L1 negative and squamous histology NSCLC patients. This is significant because these subgroups often respond poorly to other immunotherapy combinations, with Dr. Carbone noting some trials where the control arm outperformed pembrolizumab in these patients.

The focus on KRAS is expanding beyond small molecule inhibitors to diverse immunotherapies. Approaches like TCR T-cells, mRNA vaccines targeting KRAS neoepitopes, and novel amphiphil vaccines are being developed to activate a patient's immune system against their specific cancer mutations.

A new class of drugs, "RAS on" inhibitors (e.g., daxorarasib), targets the active, GTP-bound state of KRAS. This mechanism is distinct from first-generation "RAS off" inhibitors (e.g., sotorasib) and is designed to treat patients who develop resistance, offering a subsequent line of targeted therapy.

In frontline clinical trials for KRAS G12C NSCLC, combining olomorasib with pembrolizumab alone yielded a 90% response rate in patients with >50% PD-L1 expression. This surpassed the 78% rate seen when chemotherapy was added, suggesting a more targeted approach may be superior for this specific biomarker-defined subgroup.

Due to a 10-11 month overall survival benefit shown in the FLORA two regimen, leading oncologists now consider osimertinib plus chemotherapy the standard first-line treatment for metastatic EGFR-mutant NSCLC. Monotherapy is reserved only for patients who cannot tolerate or refuse chemotherapy.

Contrary to the standard 'TKI-first' approach for driver mutations, a study in MET exon 14 skipping NSCLC suggests a different strategy. Patients with high PD-L1 expression appeared to have better outcomes with first-line chemoimmunotherapy, reserving the targeted therapy for later. This challenges the conventional wisdom of prioritizing the driver mutation over immunotherapy biomarkers in this specific subgroup.

While pan-RAS inhibitors like daraxoracib show broad efficacy irrespective of mutation, allele-specific agents may have fewer side effects and more predictable resistance patterns. This creates a clinical trade-off between immediate applicability and a more tailored, potentially better-tolerated long-term strategy.